Industry seeks trust and louder voice in HTA evolution, says EFPIA
This article was originally published in Scrip
The pharmaceutical industry has so far had only narrow input into a European pilot that saw numerous health technology assessment (HTA) bodies work together to assess the relative effectiveness of GlaxoSmithKline's Votrient. With greater collaboration on relative effectiveness edging forward, industry should have a bigger say on how HTA evolves, says EFPIA, the European Federation of Pharmaceutical Industry Associations.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.